Risk factors

Nomad Power Solutions faces going concern doubts and has no revenue, relying on unproven early-stage cancer research like lead product LB-100.

NextPlat relies heavily on Amazon and Alibaba marketplaces, generating 32.8% of 2024 sales on Amazon and 67% internationally. The company faces ongoing net losses, posting a $23.1 million net loss in 2024 and an accumulated deficit of $49.0 million. Operations span diverse sectors including pharmacy services, e-commerce, and satellite tracking device development.

Oklo faces high risks from its lack of commercial operating experience, uncertain regulatory approvals for first-of-a-kind nuclear facilities, and unproven supply chains. The company depends heavily on early customer agreements like the Equinix LOI and must navigate complex government policies and public perception.

Palisade Bio faces substantial going concern doubt with net losses of $14.4 million for 2024 and insufficient capital to complete development. The company relies entirely on its lead asset PALI-2108, currently in a Phase 1 clinical trial in Canada for ulcerative colitis. Operations depend heavily on third-party manufacturers, license agreements like the Giiant agreement, and additional equity financing.

UiPath dominates its risk profile around reliance on the UiPath Platform, AI adoption challenges, customer concentration, and intense market competition.

Going concern doubts exist as operations require additional capital to fund beyond March 2026. Common stock closed below the one dollar minimum bid price required for Nasdaq listing. Subsidiary reliance is critical as direct fundraising at PAVmed faces severe market challenges.

Substantial doubt exists regarding the company's ability to continue as a going concern due to debt refinancing uncertainty.

Quince Therapeutics depends entirely on the clinical and commercial success of its lead drug candidate, eDSP, for A-T.

Serina Therapeutics relies entirely on its unproven POZ Platform drug delivery technology for preclinical pipeline development. The company faces persistent operating losses, total revenue absence, and a critical need for external financing. Regulatory hurdles, reliance on third-party manufacturers, and intellectual property protection dominate the risk profile.

Substantial history of net losses and accumulated deficit threatening ongoing business operations as a going concern.

TransAct Technologies faces risks regarding operating cash flow volatility, customer concentration with major gaming companies, and maintaining sufficient credit facility borrowing capacity.

Veeva faces critical transition risks migrating CRM customers from Salesforce to its own Vault CRM platform by 2030. Revenue concentration is high, with the top 10 customers generating 28% of total revenues in fiscal 2025. Strict life sciences regulations, third-party data dependencies, and new AI adoption risks heavily impact operations.